Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a research note issued to investors on Friday, Benzinga reports. They presently have a $30.00 price target on the stock.
Sonnet BioTherapeutics Stock Performance
Shares of SONN traded up $0.03 during mid-day trading on Friday, hitting $0.73. The company’s stock had a trading volume of 11,272 shares, compared to its average volume of 94,653. The firm has a 50-day moving average price of $0.90 and a 200 day moving average price of $1.48. Sonnet BioTherapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $6.60.
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.06. Sonnet BioTherapeutics had a negative net margin of 11,187.19% and a negative return on equity of 382.31%. Equities research analysts anticipate that Sonnet BioTherapeutics will post -2.14 EPS for the current fiscal year.
Institutional Investors Weigh In On Sonnet BioTherapeutics
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Featured Articles
- Five stocks we like better than Sonnet BioTherapeutics
- What is an Earnings Surprise?
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- 3 REITs to Buy and Hold for the Long Term
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.